Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priscilla A. Hollander

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Postgraduate Medicine|December 12, 2017
New oral agents for type II diabetesPriscilla A Hollander
Medgenmed : Medscape General Medicine|April 17, 2007
Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetesPriscilla A Hollander
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|February 1, 2012
Insulin detemir for the treatment of obese patients with type 2 diabetesPriscilla A Hollander
Postgraduate Medicine|May 14, 2010
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitorsPriscilla A Hollander, Pamela Kushner
The American Journal of Medicine|April 23, 2017
Where Are We Now? A Clinicians' Guide to the Use of Follow-On Insulin for Patients with DiabetesSteven V Edelman, Priscilla A Hollander, Eugene E Wright
Diabetes, Obesity & Metabolism|July 3, 2019
Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self-titrating insulin glargine U-100Priscilla A Hollander, Jacek Kiljanski, Erik Spaepen, et al.
Diabetes Care|December 17, 2009
Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trialPriscilla A Hollander, Aslam Amod, León E Litwak, et al.
Diabetes Technology & Therapeutics|February 16, 2010
Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetesPriscilla A Hollander, William T Cefalu, Michael Mitnick, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 16, 2018
Similar Efficacy and Safety of Basaglar<sup>®</sup> and Lantus<sup>®</sup> in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 StudyRobyn K Pollom, Timothy Costigan, Lyndon B Lacaya, et al.
European Journal of Internal Medicine|January 16, 2007
Basal insulin or premix analogue therapy in type 2 diabetes patientsPhilip R Raskin, Priscilla A Hollander, Andrew Lewin, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Postgraduate Medicine|December 12, 2017
New oral agents for type II diabetesPriscilla A Hollander
Medgenmed : Medscape General Medicine|April 17, 2007
Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetesPriscilla A Hollander
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|February 1, 2012
Insulin detemir for the treatment of obese patients with type 2 diabetesPriscilla A Hollander
Postgraduate Medicine|May 14, 2010
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitorsPriscilla A Hollander, Pamela Kushner
The American Journal of Medicine|April 23, 2017
Where Are We Now? A Clinicians' Guide to the Use of Follow-On Insulin for Patients with DiabetesSteven V Edelman, Priscilla A Hollander, Eugene E Wright
Diabetes, Obesity & Metabolism|July 3, 2019
Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self-titrating insulin glargine U-100Priscilla A Hollander, Jacek Kiljanski, Erik Spaepen, et al.
Diabetes Care|December 17, 2009
Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trialPriscilla A Hollander, Aslam Amod, León E Litwak, et al.
Diabetes Technology & Therapeutics|February 16, 2010
Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetesPriscilla A Hollander, William T Cefalu, Michael Mitnick, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 16, 2018
Similar Efficacy and Safety of Basaglar<sup>®</sup> and Lantus<sup>®</sup> in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 StudyRobyn K Pollom, Timothy Costigan, Lyndon B Lacaya, et al.
European Journal of Internal Medicine|January 16, 2007
Basal insulin or premix analogue therapy in type 2 diabetes patientsPhilip R Raskin, Priscilla A Hollander, Andrew Lewin, et al.
Pageof 3